Atara Biotherapeutics, Inc. ã¯æ¢è£œã® T 现èå
ç«çæ³äŒç€Ÿã§ãç±³åœã§ãããèªå·±å
ç«çŸæ£ããŠã€ã«ã¹æ§çŸæ£ã®æ£è
åãã®æ²»çæ³ãéçºããŠããŸããå瀟ã¯ããšãã¹ã¿ã€ã³ã»ããŒãŠã€ã«ã¹ (EBV) ã«ããç§»æ€åŸãªã³ã墿®æ§çŸæ£ããªãã³ã«éŒ»åœé ãããªã©ã®è¡æ¶²è
«çããã³åºåœ¢è
«çã®æ²»çãç®çãšãã第 3 çžèšåºè©Šéšäžã® T 现èå
ç«çæ³ã§ãã tabelecleucel ãéçºããŠããŸããå瀟ã¯ãŸããã¡ãœããªã³çšã® ATA2271 ããã³ ATA3271ãB çŽ°èæªæ§è
«ççšã® ATA2431 ããã³ ATA3219ãå€çºæ§ç¡¬åçã®æ²»çè¬ ATA188 ãªã©ãè¡æ¶²æªæ§è
«çããã³åºåœ¢è
«çã®æ£è
åãã®æ¬¡äžä»£ CAR T å
ç«çæ³ãéçºããŠããŸããããã«ãåç€Ÿã¯æ¥æ§éªšé«æ§çœè¡ç
çšã® ATA2321 ãéçºããŠããŸãããŸããããããããŒããŠã€ã«ã¹çšã®ATA368ãéçºããŠããŸããAtara Biotherapeutics, Inc.ã¯ãã¡ã¢ãªã¢ã«ã»ã¹ããŒã³ã»ã±ã¿ãªã³ã°ããã»ã³ã¿ãŒãšã©ã€ã»ã³ã¹å¥çŽãç· çµããŠããŸãããŸããQIMRãã«ã¯ããŒãã¡ãŒå»åŠç ç©¶æãšã©ã€ã»ã³ã¹ããã³ç ç©¶éçºååå¥çŽãç· çµããŠããŸããããã«ãåºåœ¢è
«çã«å¯Ÿããã¡ãœããªã³æšçCAR T现èçæ³ã«é¢ããŠãH.ãªãŒã»ã¢ãã£ããããã»ã³ã¿ãŒããã³ãã€ãšã«AGãšæŠç¥çææºãçµãã§ããŸããå瀟ã¯2012幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµãŠã¹ãµã³ãã©ã³ã·ã¹ã³ã«æ¬ç€Ÿã眮ããŠããŸãã